Wada, Iori
Nakao, Shintaro https://orcid.org/0000-0003-4200-0052
Fukuda, Yosuke
Shiose, Satomi
Takeda, Atsunobu
Kannan, Ram
Sonoda, Koh-Hei
Funding for this research was provided by:
JSPS KAKENHI (20K09829)
Alcon Pharma Research Grants
The Foundation for The Advancement of Clinical Medicine
NIH (EY30141)
William Keck Foundation
Article History
Received: 11 July 2022
Revised: 8 February 2023
Accepted: 18 February 2023
First Online: 4 March 2023
Change Date: 22 August 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00417-023-06214-x
Declarations
:
: All animal experiments were approved by the Animal Care Committee of Kyushu University (A21-013). All experimental procedures on the animals were performed according to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Moreover, this study was approved by the institutional ethics committees of Kyushu University Hospital (28–473, UMIN 000028656), and was performed in accordance with the tenets of the Declaration of Helsinki.
: Written informed consent was obtained from all patients.
: Shintaro Nakao: consulting fee by Kowa; travel reimbursements and speaker fees from Novartis, Bayer Pharma, Canon Inc., Santen Pharmaceutical, Kowa, Senju Pharmaceutical, Ono Pharmaceutical, and MSD. Koh-Hei Sonoda: consulting fees from Kowa, JT, and AbbVie; travel reimbursements and speaker fees from Novartis, Bayer Pharma, Canon Inc., Santen Pharmaceutical, Kowa, Senju Pharmaceutical, Ono Pharmaceutical, MSD, HOYA, Wakamoto, AMO, Alcon, Otsuka Pharmaceutical, AbbVie Eisai, Nidek, Topcon, Novo Nordisk, Mitsubishi Tanabe Pharma, Sumitomo Dainippon Pharma, and Astellas. The following authors have no financial disclosures: Iori Wada, Yosuke Fukuda, Satomi Shiose, Atsunobu Takeda, and Ram Kannan. All authors attest that they met the current ICMJE criteria for authorship.